The overview: about $95 to $110 billion of outside spending

[Chart: Grand View Research, Global Market Insights, Precedence Research, IMARC, ResearchAndMarkets, Straits, Coherent (2025-2026 releases). See the live document for the chart.]

Workload (from our ranking)MarketLatest sizeForecastGrowth a year
1. Clinical developmentCRO / clinical trial services$57.5 to 59.6B (2025)about $106B (2033 to 2035)6.5 to 7.5%
1. Clinical developmenteClinical software (EDC, CTMS)$11.4 to 11.5B$25.9 to 35.1B (2033 to 2034)8 to 15%
2. Regulatory submissionsRegulatory affairs outsourcing$7.5B (2024) to $8.9B (2025)$15.7 to 16.2B (2034)7 to 7.6%
2. Regulatory submissionsMedical writing$5.1B (2025)$10.3 to 11.1B (2032 to 2033)about 10%
3. PharmacovigilancePV services and software$8.6 to 11.8B (2025)$13.5 to 24.8B (2030 to 2034)5.6 to 15.9%
4. Quality and GMPLife sciences QMS software$3.7 to 3.9B (2025)$10.1 to 11.4B (2033 to 2034)12.8 to 13.8%
Cross-cuttingAI in drug discovery$2.3 to 6.9B (2025)$13.8 to 16.5B (2033 to 2034)10 to 25%

Adding the low and high ends of the services and software markets gives roughly $95 to $110 billion a year (our arithmetic; markets may overlap). Clinical trial services alone are about 55 to 60% of that. The fastest growth is in software and AI, not in services.

Clinical development: CROs and eClinical software

CROs are the biggest single market.

  • Grand View Research puts the healthcare contract research market at $59.6 billion in 2025, growing 7.5% a year to $105.7 billion by 2033. North America holds 40.2% and clinical work 75.4%, and oncology is the largest therapy area (30.8%).
  • Global Market Insights’ estimate is similar: $57.5 billion, reaching $107.6 billion by 2035.
  • Research firms cite rising trial complexity and outsourcing by drug developers as growth drivers. That matches the protocol data in our workload article.

Company revenue as a reality check (2025):

CompanyRevenueBacklog
IQVIA, R&D Solutions segment$8.9 billion$32.7 billion
ICON$8.3 billion (+0.8%)$21.8 billion
Medpace$2.5 billion (+20%)$3.0 billion

IQVIA and ICON alone account for about $17 billion, close to 30% of the market estimates.

eClinical software (electronic data capture, trial management) is about $11.4 to 11.5 billion. Grand View forecasts 15% growth a year to 2033, and Precedence 8%. One major listed supplier reported $3.2 billion of total revenue in its fiscal year to January 2026, up 16%.

Regulatory, safety, quality, and AI

Regulatory affairs outsourcing.

  • IMARC: $8.9 billion in 2025, reaching $16.2 billion by 2034 (6.9% a year).
  • Global Market Insights: $7.5 billion in 2024, reaching $15.7 billion by 2034 (7.6% a year).

Medical writing. Grand View and Coherent both put it at about $5.1 billion in 2025, growing about 10% a year. Medical writing is the main workload for clinical study reports and submission documents. One firm’s page shows a figure around 35 times higher, which looks like an error, and we have not used it.

Pharmacovigilance. Estimates range from $8.6 billion (Grand View) to $11.8 billion (ResearchAndMarkets) in 2025. Forecast growth ranges from 5.6% to 15.9% a year, depending on whether the estimate covers outsourced services, software, or both. With FDA receiving about 2.2 million electronic adverse event submissions a year, case processing is the main cost: Deloitte (2019) found it takes 40 to 85% of pharmacovigilance budgets.

Quality management software (QMS).

  • Grand View: $3.7 billion in 2025 for life sciences QMS software, growing 13.8% a year to $10.1 billion by 2033.
  • Straits: $3.87 billion, reaching $11.4 billion by 2034.

AI. This is the smallest market today, but the fastest growing.

Market2025 sizeForecastGrowth a yearSource
AI in drug discovery$2.3B$13.8B (2033)24.8%Grand View
AI in drug discovery$6.9B$16.5B (2034)10.1%Precedence
AI in life sciences$2.7B$15.9B (2035)19.3%Precedence
Generative AI in life sciences$0.3B$1.7B (2034)20.8%Towards Healthcare / Precedence

McKinsey estimates generative AI’s potential value in pharma at $60 to 110 billion a year. That is many times today’s AI market, which suggests large room for growth.

Why estimates differ

  • Scope. “Pharmacovigilance” may mean outsourced services, software, or both. “AI in drug discovery” may or may not include clinical development.
  • Base year. Some firms report 2024 and others 2025.
  • Errors. One medical writing estimate was about 35 times higher than the others. Always compare at least two sources.
  • Paid releases. Many figures come from press releases distributed by the research firms themselves. Company revenue is the best check.

Using market data in AI and RAG

  1. Store each estimate with its firm, scope, base year, and release date.
  2. Show ranges where firms differ.
  3. Anchor to company filings (IQVIA, ICON, Medpace and listed software suppliers) for verifiable figures.
  4. Map each market to the workload it serves, as in the overview table.

Common mistakes

  • Quoting a single firm’s figure as “the” market size.
  • Adding overlapping markets, such as eClinical software and CRO services, without noting the overlap.
  • Comparing forecasts that end in different years.
  • Using outlier figures without checking them.

Checklist

  • Two or more sources per market
  • Scope and base year recorded
  • Company revenue used as a check
  • Outliers flagged

How AskDona helps

AskDona sits where these markets overlap: the documents behind clinical, regulatory, safety, and quality work. Whether that work is done in-house or by a CRO or other vendor, AskDona checks it against the rules and source documents and cites the passage behind each finding.

Run a sample vendor deliverable evidence check

AskDona shows the evidence; your teams decide.

Editor’s note. This article is general information, not investment advice. Market sizes are commercial research estimates with different scopes; we show ranges and name each firm. Company figures come from 2025 annual results. Totals across markets are our arithmetic and may double-count.

FAQ

How big is the CRO market? About $57.5 to 59.6 billion in 2025, growing 6.5 to 7.5% a year.

How big is the pharmacovigilance market? About $8.6 to 11.8 billion in 2025, depending on scope.

What is the fastest-growing segment? AI and software. Life sciences QMS software is growing about 13 to 14% a year, and AI in drug discovery 10 to 25%.

Who are the largest CROs? IQVIA (R&D Solutions, $8.9 billion in 2025 revenue) and ICON ($8.3 billion).

References

All pages opened and checked by October 31, 2026.

SourceWhat it supports
Grand View: Healthcare CRO market$59.6B, 7.5%, segments
Global Market Insights: CRO market$57.5B, 2035 forecast
IQVIA: Q4 2025 results (SEC)R&D Solutions revenue, backlog
ICON: 2025 resultsICON revenue, backlog
Medpace: 2025 resultsMedpace revenue, backlog
Grand View: eClinical solutions$11.5B, 15%
Precedence via BioSpace: eClinical$11.4B, 8.1%
Life sciences cloud vendor: FY2026 results$3.2B revenue
IMARC: Regulatory affairs outsourcing$8.9B, 2034 forecast
Global Market Insights: Healthcare RA outsourcing$7.5B (2024)
Grand View: Medical writing$5.1B, 2033 forecast
Coherent via GlobeNewswire: Medical writing$5.1B, 2032 forecast
Grand View: Pharmacovigilance$8.6B, 5.6%
Precedence via BioSpace: Pharmacovigilance$10.4B, 2034 forecast
ResearchAndMarkets via GlobeNewswire: Pharmacovigilance$11.8B, 2030 forecast
Grand View: Life sciences QMS software$3.7B, 13.8%
Straits: Life sciences QMS software$3.87B, 2034 forecast
Grand View: AI in drug discovery$2.3B, 24.8%
Precedence via BioSpace: AI in drug discovery$6.9B, 10.1%
Precedence via BioSpace: AI in life sciences$2.7B, 19.3%
GlobeNewswire: Generative AI in life sciences$0.3B, 20.8%